![The Debruin family wearing green t-shirts with printed text "Wade's Army"](https://unclineberger.org/wp-content/uploads/sites/867/2020/03/debruins1-e1584624049283-600x400.jpg)
March 19, 2020
Donor gift shows support for family, innovative therapy
Wade's Army supports families with needs related to a neuroblastoma diagnosis, and supports research and science into finding a cure for the disease.
March 19, 2020
Wade's Army supports families with needs related to a neuroblastoma diagnosis, and supports research and science into finding a cure for the disease.
March 12, 2020
When his lymphoma recurred just 18 months after treatment, Jeff Nichols enrolled in a CAR-T clinical trial at UNC Lineberger.
March 9, 2020
Donielle DuBois traveled to Chapel Hill to receive CAR-T immunotherapy for her Hodgkin lymphoma, which had recurred after being in remission for several years.
March 9, 2020
An investigational therapy for Hodgkin lymphoma received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.
February 13, 2020
When traditional cancer treatment options failed, Sabrina Shelton's care team referred her to UNC for a CAR-T therapy clinical trial.
January 30, 2020
A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects. In a study published in Cancer Cell, researchers led by UNC Lineberger’s Gianpietro Dotti, …
May 20, 2019
Jonathan Serody, MD, explains in a two-minute video the action behind chimeric antigen T-cell, or CAR-T, immunotherapy and how UNC Lineberger is designing, developing and delivering CAR-T therapies to treat cancers that fail to respond to standard treatments.
November 27, 2018
October 23, 2018
Gianpietro Dotti, MD, will use the $100,000 grant to conduct research into the use of cellular immunotherapy to treat solid tumors such as neuroblastoma, glioblastoma, ovarian cancer, pancreatic cancer and triple negative breast cancer.
February 28, 2018
A team led by UNC Lineberger's Gianpietro Dotti, MD, has engineered immune cells to hunt glioblastoma, the most lethal primary brain tumor. They presented their findings in Science Translational Medicine.